858 Therapeutics
8five8tx.com
Actively hiring
Health Care
Biotechnology
Oncology Therapeutics
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$65.2M
3 rounds on record
Latest round
$25.2M
Venture round · Jun 2024 · 2 yr ago
Team
201-500
employees, estimated range
Backers
1
NEA
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 26, 2024
Raised a round Venture round $25.2M · SEC Form D
May 4, 2021
Raised a round Venture round $20M · SEC Form D
Mar 3, 2020
Raised a round Venture round $20.1M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2024 | $25.2M | — | SEC Form D |
| Venture round | May 2021 | $20M | — | SEC Form D |
| Venture round | Mar 2020 | $20.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | 858 Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Stafford JeffreyExecutive Officer, DirectorSEC Form D
James VealExecutive OfficerSEC Form D
Katherine Bell-McGuinnExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
NEA Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
SirnaMed is committed to developing innovative therapies that directly target the cause of cancer development, progression and treatment…
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune…
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
Overview
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for patients with advanced solid tumors.
People
Stafford Jeffrey
Executive Officer, Director
James Veal
Executive Officer
Katherine Bell-McGuinn
Executive Officer
Clare Ozawa
Director
Ali Behbahani
Director
Monal Mehta
Director
Jane Huang
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego
United States
HQ
3115 Merryfield Row, Suite 110San Diego, CA 92121
200-500 est. staff
3115 Merryfield Row, Suite 110, San Diego, CA 92121